热门资讯> 正文

Sarepta关注即将发布的Elevidys 3年数据

2026-01-24 06:55

Sarepta疗法(SRPT) 0

Sarepta Therapeutics (SRPT) is up ~10% in after-hours trading Friday after announcing it will release topline, 3-year results from its EMBARK study of Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy the morning of Jan. 26.
The data from part 1 is in ambulatory patients with Duchenne who were four to seven years old at time of treatment.
The company will hold a webcast and conference call at 830a ET on Jan. 26.

More on Sarepta Therapeutics

Sarepta Preliminary Results: Not What The Market Wanted To Hear
Sarepta Therapeutics: Is Elevidys A Bust?
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
Sarepta guides Q4 sales below estimates
Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。